• OPEN AN ACCOUNT
Indian Indices
Nifty
24,734.30 19.25
(0.08%)
Sensex
80,470.86 -247.15
( -0.31%)
Bank Nifty
54,075.45 7.90
( 0.01%)
Nifty IT
35,143.10 -331.85
( -0.94%)
Global Indices
Nasdaq
45,627.16 334.92
(0.74%)
Dow Jones
6,520.86 51.60
(0.80%)
Hang Seng
42,984.31 404.04
(0.95%)
Nikkei 225
9,216.87 38.88
(0.42%)
Forex
USD-INR
88.06 0.00
(0.00%)
EUR-INR
102.58 -0.09
(-0.08%)
GBP-INR
118.07 -0.20
(-0.17%)
JPY-INR
0.59 0.00
(-0.15%)

EQUITY - MARKET SCREENER

Ambey Laboratories Ltd
Industry :  Pesticides / Agrochemicals - Indian
BSE Code
ISIN Demat
Book Value()
92828
INE0M3I01029
26.3948758
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
AMBEY
22.06
105.65
EPS(TTM)
Face Value()
Div & Yield %
1.92
10
0
 

arcee industries ltd
Sun Pharma drops as foreign broker downgrades on valuation, execution risks
Aug 26,2025
The broker cited stretched valuations and slower-than-expected traction in speciality drugs. It flagged concerns around psoriasis drug Ilumya's heavy Medicare exposure, potential pricing pressures, and limited earnings visibility despite strong initial uptake. It warned that a 10% price cut in Ilumya could erode Sun Pharma’s EPS by 4%.

Sun Pharmaceutical Industries is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets.

The company’s consolidated net profit tumbled 19.64% to Rs 2,278.63 crore despite of 10.07% increase in revenue from operations to Rs 13,786.07 crore in Q1 FY26 over Q1 FY25. The drop in profit was primarily due to a one-time exceptional charge of Rs 818 crore during the quarter.